General Information of Drug (ID: DML10K3)

Drug Name
SF1126 Drug Info
Synonyms CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt
Indication
Disease Entry ICD 11 Status REF
Head and neck cancer 2D42 Phase 2 [1]
Hepatocellular carcinoma 2C12.02 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
66577114
TTD Drug ID
DML10K3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sirolimus DMGW1ID Advanced cancer 2A00-2F9Z Approved [4]
Temsirolimus DMS104F Renal cell carcinoma 2C90 Approved [5]
PF-04449913 DMSB068 Chronic myelomonocytic leukaemia 2A40 Approved [6]
Everolimus DM8X2EH Advanced cancer 2A00-2F9Z Approved [7]
Novolimus DM6ZPLQ Artery stenosis BD52 Approved [8]
Zotarolimus DMRMCXW Solid tumour/cancer 2A00-2F9Z Approved [9]
Ridaforolimus DMLHEU7 Sarcoma 2A60-2C35 Phase 3 [10]
AZD2014 DMOEARH Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
MM-141 DM2RJ4D Pancreatic cancer 2C10 Phase 2 [1]
PQR309 DMMCYZ8 Squamous head and neck cell carcinom 2D60.0 Phase 2 [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting PI3-kinase gamma (PIK3CG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BAY 80-6946 DMLOS5R Follicular lymphoma 2A80 Approved [12]
IPI-145 DMWA24P Follicular lymphoma 2A80 Approved [13]
Buparlisib DM1WEHC Breast cancer 2C60-2C65 Phase 3 [14]
Enzastaurin DM5H0R9 Diffuse large B-cell lymphoma 2A81 Phase 3 [1]
Rigosertib DMOSTXF Myelodysplastic syndrome 2A37 Phase 3 [15]
GDC-0032 DMT4QHD Breast cancer 2C60-2C65 Phase 3 [1]
PQR309 DMMCYZ8 Squamous head and neck cell carcinom 2D60.0 Phase 2 [16]
SAR245409 DMQM7IL Solid tumour/cancer 2A00-2F9Z Phase 2 [17]
XL147 DMML7BE Solid tumour/cancer 2A00-2F9Z Phase 2 [17]
PF-05212384 DMBL3VD Solid tumour/cancer 2A00-2F9Z Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PI3-kinase gamma (PIK3CG) TTHBTOP PK3CG_HUMAN Modulator [3]
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026065)
3 An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Cancer Chemother Pharmacol.2013 Apr;71(4):867-81.
4 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
5 Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
9 Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
10 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
11 Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
12 BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30.
13 PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
14 Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
15 Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156).
18 First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95.